Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).

A novel series of 1,2,4-thiadiazole compounds was discovered as selective S1P(1) agonists. The extensive structure-activity relationship studies for these analogues were reported. Among them, 17g was identified to show high in vitro potency with reasonable free unbound fraction in plasma (F(u) > 0.5%), good brain penetration (BBR > 0.5), and desirable pharmacokinetic properties in mouse and rat. Oral administration of 1 mg/kg 17g resulted in significant peripheral lymphocytes reduction at 4 h after dose and rapid lymphocytes recovery at 24 h. 17g showed a transient lymphopenia profile in the repeated dose study in mouse. In addition, 17g also demonstrated efficacy comparable to that of FTY720 (1) in the mouse EAE model of MS.

[1]  S. Ludwin,et al.  Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. , 2010, The American journal of pathology.

[2]  M. Bolli,et al.  2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. , 2010, Journal of medicinal chemistry.

[3]  F. Tse,et al.  Quantitative determination of BAF312, a S1P-R modulator, in human urine by LC-MS/MS: prevention and recovery of lost analyte due to container surface adsorption. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  Jingwu Z. Zhang,et al.  Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease , 2010, Nature Medicine.

[5]  D. Verzijl,et al.  Sphingosine-1-phosphate receptors: Zooming in on ligand-induced intracellular trafficking and its functional implications , 2010, Molecules and cells.

[6]  L. Sorbera,et al.  Therapeutic targets for multiple sclerosis , 2009, Drugs of the Future.

[7]  Robert M. Jones,et al.  Recent progress in the development of selective S1P1 receptor agonists for the treatment of inflammatory and autoimmune disorders , 2008 .

[8]  J. Kovarik,et al.  The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects , 2008, European Journal of Clinical Pharmacology.

[9]  M. Wenlock,et al.  The Role of Plasma Protein Binding in Drug Discovery , 2007 .

[10]  G. Chrebet,et al.  SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties. , 2007, Bioorganic & medicinal chemistry letters.

[11]  J. Kovarik,et al.  FTY720: Placebo‐Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects , 2006, Journal of clinical pharmacology.

[12]  G. Chrebet,et al.  Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes. , 2006, Bioorganic & medicinal chemistry letters.

[13]  G. Chrebet,et al.  Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor. , 2006, Bioorganic & Medicinal Chemistry Letters.

[14]  G. Chrebet,et al.  2-Aryl(pyrrolidin-4-yl)acetic acids are potent agonists of sphingosine-1-phosphate (S1P) receptors. , 2006, Bioorganic & medicinal chemistry letters.

[15]  R. Proia,et al.  Essential Role for Sphingosine Kinases in Neural and Vascular Development , 2005, Molecular and Cellular Biology.

[16]  S. Enosawa,et al.  KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts , 2005, Circulation.

[17]  J. Cyster,et al.  FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  R. Proia,et al.  Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[19]  R. Proia,et al.  Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration* , 2004, Journal of Biological Chemistry.

[20]  N. Gray,et al.  Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate* , 2004, Journal of Biological Chemistry.

[21]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[22]  F. Lublin,et al.  Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.

[23]  H. Hui,et al.  Environmentally friendly and efficient: iron-mediated reduction of 3-methyl-5-aryl-1,2,4-oxadiazoles to benzamidines , 2003 .

[24]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[25]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[26]  R Scott Obach,et al.  Biotransformation reactions of five-membered aromatic heterocyclic rings. , 2002, Chemical research in toxicology.

[27]  Clive W. Bird,et al.  The application of a new aromaticity index to six-membered ring heterocycles , 1986 .

[28]  C. W. Bird.  A new aromaticity index and its application to five-membered ring heterocycles , 1985 .

[29]  S. Lan,et al.  Metabolic studies with trans-5-amino-3-(2-(5-nitro-2-furyl)vinyl)-1,2,4-(5- 14 C)oxadiazole (SQ 18,506). 1. Reductive cleavage of the 1,2,4-oxadiazole ring. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.